CM
FLXN

Castleark Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Castleark Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-164,185
Closed -$3.4M – 409
2019
Q4 		$3.4M Buy
+164,185
New +$2.77M 0.14% 189
2018
Q3 		– Sell
-112,265
Closed -$2.9M – 422
2018
Q2 		$2.9M Buy
+112,265
New +$2.91M 0.09% 227

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Castleark Management's FLXN Position: Q1 2020 in Review

Castleark Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q1 2020, closing a stake of 164,185 shares — an estimated $3.4M sold.

Castleark Management first reported a position in FLXN in Q2 2018 and held it in 2 quarters. The position peaked at $3.4M in Q4 2019. 123 funds tracked by Wall St. Rank hold FLXN as of Q1 2020.

  • Castleark Management reported no remaining Flexion Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Castleark Management sold 164,185 Flexion Therapeutics, Inc. shares in Q1 2020, an estimated $3.4M.
  • Castleark Management first reported a position in Flexion Therapeutics, Inc. in Q2 2018 and held it in 2 quarters.
  • Castleark Management's Flexion Therapeutics, Inc. position peaked at $3.4M in Q4 2019.
  • 123 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q1 2020.

Based on Castleark Management's 13F filing for Q1 2020, filed 13 May 2020.